Journal
CANCER DRUG RESISTANCE
Volume 3, Issue 1, Pages 48-62Publisher
OAE PUBLISHING INC
DOI: 10.20517/cdr.2019.105
Keywords
Cyclin-dependent kinases; cyclin-dependent kinase inhibitors; gliomas; glioblastoma; clinical trials; resistance
Categories
Funding
- European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant [766069]
Ask authors/readers for more resources
Cyclin-dependent kinases (CDKs) are important regulatory enzymes in the normal physiological processes that drive cell-cycle transitions and regulate transcription. Virtually all cancers harbour genomic alterations that lead to the constitutive activation of CDKs, resulting in the proliferation of cancer cells. CDK inhibitors (CKIs) are currently in clinical use for the treatment of breast cancer, combined with endocrine therapy. In this review, we describe the potential of CKIs for the treatment of cancer with specific focus on glioblastoma (GBM), the most common and aggressive primary brain tumour in adults. Despite intense effort to combat GBM with surgery, radiation and temozolomide chemotherapy, the median survival for patients is 15 months and the majority of patients experience disease recurrence within 6-8 months of treatment onset. Novel therapeutic approaches are urgently needed for both newly diagnosed and recurrent GBM patients. In this review, we summarise the current preclinical and clinical findings emphasising that CKIs could represent an exciting novel approach for GBM treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available